Halo's lead program, H01, is a small-molecule first-in-class inhibitor of HA synthesis with Phase 2a proof of concept clinical trials initiated in pulmonary hypertension and pulmonary fibrosis.
Our pipeline includes discovery and clinical stage assets and is protected by both method-of-use and composition of matter patents in various territories.
Targeting Hyaluronan (HA) is a novel, differentiated mechanism with potential to transform disease states
Halo is a team of leaders in HA biology and drug development. We are closely connected to Stanford University's unparalleled ecosystem of drug discovery.
Learn more about Halo, our pipeline, and our work in pulmonary hypertension and interstitial lung diseases
Copyright © 2024 Halo Biosciences - All Rights Reserved.